Avion Pharms Company Profile

What is the competitive landscape for AVION PHARMS

AVION PHARMS has three approved drugs.

There are four US patents protecting AVION PHARMS drugs.

There are ten patent family members on AVION PHARMS drugs in seven countries and fifteen supplementary protection certificates in eight countries.

Summary for Avion Pharms

International Patents:	10
US Patents:	4
Tradenames:	3
Ingredients:	3
NDAs:	3

Drugs and US Patents for Avion Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avion Pharms	BALCOLTRA	ethinyl estradiol; levonorgestrel	TABLET;ORAL	208612-001	Jan 9, 2018	AB3	RX	Yes	Yes	7,838,042			Y
Avion Pharms	DHIVY	carbidopa; levodopa	TABLET;ORAL	214869-001	Nov 12, 2021		RX	Yes	Yes	11,439,613
Avion Pharms	DHIVY	carbidopa; levodopa	TABLET;ORAL	214869-001	Nov 12, 2021		RX	Yes	Yes	11,819,485
Avion Pharms	DHIVY	carbidopa; levodopa	TABLET;ORAL	214869-001	Nov 12, 2021		RX	Yes	Yes	11,033,521		Y
Avion Pharms	PONSTEL	mefenamic acid	CAPSULE;ORAL	015034-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

Expired US Patents for Avion Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Avion Pharms	BALCOLTRA	ethinyl estradiol; levonorgestrel	TABLET;ORAL	208612-001	Jan 9, 2018	6,716,814

International Patents for Avion Pharms Drugs

Country	Patent Number	Estimated Expiration
Canada	3095341
China	111954523
European Patent Office	3773532
Japan	2021517128
Japan	2022133449
World Intellectual Property Organization (WIPO)	2019191353

Supplementary Protection Certificates for Avion Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0771217	07C0001	France		PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
1453521	39/2015	Austria		PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
0398460	C300221	Netherlands		PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
0771217	CA 2006 00038	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
1380301	CA 2009 00017	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
1214076	SZ 49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Avion Pharms

Pharmaceutical Competitive Landscape Analysis: Avion Pharmaceuticals – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, understanding the competitive landscape is crucial for success. Avion Pharmaceuticals, a specialty pharmaceutical company, has carved out a unique position in this complex industry. This analysis delves into Avion's market position, strengths, and strategic insights, providing a comprehensive overview of its competitive landscape.

Avion Pharmaceuticals: Company Overview

Avion Pharmaceuticals, LLC, founded in 2011, is a specialty pharmaceutical company based in Alpharetta, Georgia[2]. The company has established itself as a significant player in the pharmaceutical industry, focusing on developing and marketing innovative, branded prescription pharmaceuticals and dietary supplements[6].

Core Focus Areas

Avion specializes in several key therapeutic areas:

1. Women's Health
2. Hematology
3. Endocrinology
4. Dermatology

This targeted approach allows Avion to concentrate its resources and expertise on specific medical needs, positioning itself as a specialist rather than a generalist in the pharmaceutical landscape.

Market Position and Product Portfolio

Avion Pharmaceuticals has strategically positioned itself in the market by focusing on niche areas with high unmet medical needs. This approach has allowed the company to develop a diverse and innovative product portfolio.

Women's Health

In the women's health sector, Avion offers:

• Advanced nutritional support for preconception through postpartum
• Effective, low-dose, balanced birth control options
• Transdermal menopause symptom treatments[6]

Other Therapeutic Areas

Avion's product range extends to:

• Support for patients with Parkinson's Disease
• Prescription iron supplements designed for optimized absorption
• Support for patients with hypothyroidism[6]

This diverse portfolio demonstrates Avion's commitment to addressing various medical needs across different therapeutic areas.

Competitive Strengths

Avion Pharmaceuticals has several key strengths that contribute to its competitive position in the pharmaceutical industry:

1. Innovation Focus

Avion places a strong emphasis on identifying opportunities to develop, acquire, and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs[1]. This focus on innovation allows the company to stay at the forefront of pharmaceutical advancements.

2. Specialized Expertise

By concentrating on specific therapeutic areas, Avion has developed specialized expertise that sets it apart from more generalized pharmaceutical companies. This focused approach allows for deeper understanding and more targeted solutions in its chosen fields.

3. Strong Corporate Culture

"At Avion and Acella we are dedicated to having a high moral standard. I'm proud to say we are transparent to a fault. Our leaders work and live through the philosophy of treating others the way they want to be treated." - Art Deas, Avion's chief executive officer[1]

This commitment to a positive corporate culture has earned Avion recognition as a "Best Place to Work in Medical Sales" for two consecutive years[1]. A strong corporate culture can lead to higher employee satisfaction and productivity, ultimately contributing to the company's success.

4. Strategic Partnerships

Avion has demonstrated its ability to form strategic partnerships, as evidenced by its collaboration with ImmuPharma for the development of Lupuzor™, a potential treatment for lupus[4]. Such partnerships allow Avion to expand its reach and capabilities.

5. Patient-Centric Approach

Avion's focus on fulfilling unmet medical and dietary needs[6] indicates a patient-centric approach. This strategy not only addresses critical gaps in the current treatment landscape but also aligns with growing trends in healthcare towards more personalized and patient-focused care.

Market Strategies and Growth

Avion Pharmaceuticals has employed several strategies to strengthen its market position and drive growth:

Acquisition and Enhancement

Avion's business model focuses on identifying opportunities to acquire and enhance the market potential of existing products[6]. This strategy allows the company to expand its portfolio efficiently while leveraging its expertise to improve and market these products.

Research and Development

While specific R&D expenditures are not publicly available, Avion's focus on innovative products suggests a significant investment in research and development. The company has filed at least three patents, indicating ongoing efforts in drug development[2].

Market Expansion

Avion has shown a willingness to expand into new markets and therapeutic areas. For example, its partnership with ImmuPharma for Lupuzor™ demonstrates an interest in expanding into the autoimmune disease market[4].

Competitive Landscape

While Avion Pharmaceuticals has carved out a unique position in the market, it operates in a highly competitive industry. Some of its competitors include:

1. Large pharmaceutical companies with diverse portfolios
2. Specialty pharmaceutical companies focusing on similar therapeutic areas
3. Generic drug manufacturers

Avion's focus on niche markets and innovative products helps differentiate it from larger, more diversified competitors. However, it must continue to innovate and adapt to maintain its competitive edge.

Financial Performance

While detailed financial information is not publicly available, some estimates provide insight into Avion's financial performance:

• Estimated annual revenue: $27.7 million
• Estimated revenue per employee: $201,000
• Number of employees: Approximately 138[7]

These figures suggest that Avion operates efficiently, with a relatively high revenue per employee compared to industry averages.

Future Outlook and Challenges

Opportunities

1. Expansion into New Therapeutic Areas: Avion's expertise in niche markets could be leveraged to expand into other underserved therapeutic areas.

2. International Expansion: While currently focused on the U.S. market, there may be opportunities for international growth.

3. Digital Health Integration: Incorporating digital health technologies could enhance Avion's product offerings and patient engagement.

Challenges

1. Regulatory Environment: The pharmaceutical industry is heavily regulated, and changes in regulations could impact Avion's operations.

2. Competition: Larger pharmaceutical companies with more resources could pose a threat in Avion's niche markets.

3. Drug Development Risks: The inherent risks and high costs associated with drug development could impact Avion's growth and profitability.

Strategic Recommendations

To maintain and improve its competitive position, Avion Pharmaceuticals could consider the following strategies:

1. Continued Focus on Innovation: Maintain a strong pipeline of innovative products to stay ahead of competitors.

2. Strategic Partnerships: Pursue additional partnerships to expand capabilities and market reach.

3. Digital Transformation: Invest in digital technologies to enhance operational efficiency and patient engagement.

4. Diversification: Carefully expand into new therapeutic areas to reduce reliance on current markets.

5. Talent Retention and Acquisition: Continue to foster a positive corporate culture to attract and retain top talent in the industry.

Key Takeaways

• Avion Pharmaceuticals has established a strong position in niche pharmaceutical markets, particularly in women's health, hematology, endocrinology, and dermatology.
• The company's focus on innovation, specialized expertise, and positive corporate culture are key competitive strengths.
• Avion's strategy of acquiring and enhancing existing products, combined with in-house development, has driven its growth.
• While facing challenges from larger competitors and regulatory pressures, Avion has opportunities for expansion and innovation.
• Continued focus on niche markets, strategic partnerships, and digital transformation could be key to Avion's future success in the competitive pharmaceutical landscape.

FAQs

1. What are Avion Pharmaceuticals' main therapeutic areas? Avion primarily focuses on women's health, hematology, endocrinology, and dermatology.

2. How does Avion Pharmaceuticals differentiate itself from competitors? Avion differentiates itself through its focus on niche markets, innovative product development, and strong corporate culture.

3. What is Avion Pharmaceuticals' approach to product development? Avion combines the acquisition and enhancement of existing products with in-house development of innovative therapeutics.

4. Has Avion Pharmaceuticals received any industry recognition? Yes, Avion has been recognized as a "Best Place to Work in Medical Sales" for two consecutive years.

5. What are some potential future growth areas for Avion Pharmaceuticals? Potential growth areas include expansion into new therapeutic areas, international markets, and integration of digital health technologies.

Sources cited: [1] https://www.acellapharma.com/news/avion-pharmaceuticals-llc-and-acella-pharmaceuticals-llc-awarded-2nd-consecutive-best-place-to-work-in-medical-sales-recognition/ [2] https://www.cbinsights.com/company/avion-pharmaceuticals [4] https://www.annualreports.com/HostedData/AnnualReportArchive/i/LSE_IMM_2019.pdf [6] https://avionrx.com [7] https://growjo.com/company/Avion_Pharmaceuticals